logo-loader
viewAstraZeneca

AstraZeneca stops chronic kidney disease treatment trial early after “overwhelming efficacy”

The pharma company also announced Imfinzi has been approved for small cell lung cancer in combination with chemotherapies

AstraZeneca - AstraZeneca stops trial early for “overwhelming efficacy”

AstraZeneca PLC (LON:AZN) has stopped a late-stage trial of its chronic kidney disease treatment as it showed “overwhelming efficacy”.

An independent committee advised the FTSE 100-listed company to halt the studies for Farxiga, which is already under review to treat patients with heart failure.

READ: AstraZeneca posts negative results for late-stage bladder cancer treatment

AstraZeneca will now initiate discussions with global health authorities regarding early regulatory submissions.

In a note to clients, analysts at Shore Capital said they expect Farxiga to generate US$3bn by 2024.

In a separate announcement, the pharma giant also said that its Imfinzi drug has been approved in the US as a first-line treatment for extensive-stage small cell lung cancer, in combination with chemotherapies.

Imfinzi, which has already been approved for other types of cancer, is expected to generate sales of US$2bn this year and grow to US$4bn by 2024.

AstraZeneca shares rose 1% to 6,858p on Monday morning.

-- Adds analyst comment --

Quick facts: AstraZeneca

Price: 8580 GBX

LSE:AZN
Market: LSE
Market Cap: £112.59 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amundi Physical Gold ETC: Europe's cheapest ETC now trading on the London...

Amundi Physical Gold ETC's Ashley Fagan who's head of ETF, Indexing & Smart Beta Development for UK and Ireland introduces the product to Proactive London's Andrew Scott. She says they've seen a great deal of demand from European as well as UK investors and that's what lead them to list...

1 day, 11 hours ago

2 min read